Whereas IL-13 has been a therapeutic target for asthma with ongoing clinical trials (Bagnasco et al, 2016), dupilumab, anti-IL-4Rα which inhibits both IL-4 and IL-13 signalling, has been a front-runner treatment showing efficacy in severe asthma patients (Castro et al, 2018). Here, IL4R is linked to asthma.